- DSUVIA (sufentanil sublingual tablet 30 mcg) is indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings
- First and only sufentanil sublingual tablet approved for acute pain in healthcare settings
- DSUVIA U.S. launch expected in the first quarter of 2019
- Conference-call scheduled for Monday, November 5th at 8:30 a.m. ET
PR Newswire
REDWOOD CITY, Calif., Nov. 2, 2018